Baricitinib-Impurities | Pharmaffiliates

baricitinib

Baricitinib was approved in February of 2017 as a second-line orally administered treatment for moderate to severe active rheumatoid arthritis in adults, either as a monotherapy or when combined with methotrexate.Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. Reference standards of Baricitinib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.

stdClass Object
(
    [pname] => Baricitinib - API
    [catalogue_number] => PA 29 41000
    [category_ids] => ,71,81,78,70,82,88,
    [chemical_name] => 
    [weight] => 371.42
    [form] => C16H17N7O2S
    [cas] => 1187594-09-7
    [pslug] => 1187594-09-7-baricitinib-api-pa2941000
    [latest_product] => 0
    [linkproducts] => 0
    [offers_id] => 
    [offers_name] => 
    [offers_status] => 
    [offers_start_date] => 
    [offers_end_date] => 
    [pageview] => 
    [offers_slug] => 
    [offers_product_id] => 
    [offers_product_code] => 
    [offers_master_id] => 
    [offer_percentage] => 
    [offers_product_main_cat] => 
)
PA 29 41000

Baricitinib - API


  • Catalogue No.:PA 29 41000

  • CAS :

    1187594-09-7

  • Molecular Formula : C16H17N7O2S

  • Molecular Weight : 371.42